BBOT insider disclosures
Explore public SEC filings by reporting investor and stock. Filings can appear after the activity they describe. Joint filing lines link to each reporting owner’s profile.
| Reporting investor | Security | Activity | Transaction / period | Filed | Reported amount | Source | Follow |
|---|---|---|---|---|---|---|---|
| Beltran Pedro President and CEO · Director · BridgeBio Oncology Therapeutics, Inc. | BBOT BridgeBio Oncology Therapeutics, Inc. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 41659 · SEC code covers open-market or private transactions · This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on August 19, 2026. · The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.80 to $1.94. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. | 2026-11-18 | 2026-11-20 | ≈ $3,442.67 1,870 shares/units | SEC 4 | Follow |
| Cobo Marc Principal Accounting Officer · BridgeBio Oncology Therapeutics, Inc. | BBOT BridgeBio Oncology Therapeutics, Inc. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 13734 · SEC code covers open-market or private transactions · This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on July 24, 2026. | 2026-11-13 | 2026-11-17 | ≈ $184.86 78 shares/units | SEC 4 | Follow |
Form 4 buy and sell codes cover open-market or private transactions. Form 13F shows quarterly reported holdings. Position changes can have causes other than trading. Disclosures are delayed and provided for research.